Evidence map›Paper›PMID 34858435›Full record

ArticleFrontiers in immunology2021

Severe Congenital Thrombocytopenia Characterized by Decreased Platelet Sialylation and Moderate Complement Activation Caused by Novel Compound Heterozygous Variants in

Karolina I Smolag, Marcus Fager Ferrari, Eva Zetterberg, Eva Leinoe, Torben Ek, Anna M Blom, Maria Rossing, Myriam Martin

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Journal of neuromuscular diseases · 2026
    Article
  3. [Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Hemostatic defects in congenital disorders of glycosylation.Research and practice in thrombosis and haemostasis · 2023
    Article
  8. The role of amyloid β in the pathological mechanism of GNE myopathy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Karolina I SmolagSection of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Malmö, Sweden.
Marcus Fager FerrariClinical Coagulation Research Unit, Department of Translational Medicine, Lund University, Malmö, Sweden.
Eva ZetterbergClinical Coagulation Research Unit, Department of Translational Medicine, Lund University, Malmö, Sweden.
Eva LeinoeDepartment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Torben EkChildren's Cancer Center, Queen Silvia Children's Hospital, Gothenburg, Sweden.
Anna M BlomSection of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Malmö, Sweden.
Maria RossingCenter for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Myriam MartinSection of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Malmö, Sweden.
Lund University · SECopenhagen University Hospital · DKDrottning Silvias barn- och ungdomssjukhus · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hereditary thrombocytopenias constitute a genetically heterogeneous cause of increased bleeding. We report a case of a 17-year-old boy suffering from severe macrothrombocytopenia throughout his life. Whole genome sequencing revealed the presence of two compound heterozygous variants in Methods: Sialic acid expression and FH binding to platelets and leukocytes was evaluated by flow cytometry. The binding of FH to erythrocytes was assessed indirectly by measuring the rate of complement mediated hemolysis. Complement activation was determined by measuring levels of C3bBbP (alternative pathway), C4d (classical/lectin pathway) and soluble terminal complement complex assays. Results: The proband exhibited markedly decreased expression of sialic acid on platelets and leukocytes. Consequently, the binding of FH was strongly reduced and moderate activation of the alternative and classical/lectin complement pathways was observed, together with an increased rate of erythrocyte lysis. Conclusion: We report two previously undescribed variants in

Indexed as

HeterozygoteMutationAdolescentAllelesBlood PlateletsComplement ActivationComplement System ProteinsGenetic Association StudiesGenetic Predisposition to DiseaseHemolysisHumansLeukocytesMaleMultienzyme ComplexesN-Acetylneuraminic AcidPhenotypeComplement System ProteinsMultienzyme ComplexesN-Acetylneuraminic AcidUDP-N-acetylglucosamine 2-epimerase - N-acetylmannosamine kinasecomplement activationfactor HGNEhigh-throughput nucleotide sequencingsialic acidsialylationthrombocytopenia

Identifiers

PMID34858435
PMCPMC8630651
OpenAlexW3214572498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.